Analysis of Selected Biochemical Parameters in Cerebrospinal Fluid and Peripheral Blood in the Treatment of Neuropathic Pain Using Spinal Cord Stimulation (SCS)
Launched by PAWEL SOKAL ·
Trial Information
Current as of October 15, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying how spinal cord stimulation (SCS), a treatment for nerve-related (neuropathic) pain, works in the body. Researchers are looking at certain substances in the blood and spinal fluid, such as proteins and molecules involved in inflammation and nerve signaling, to better understand how SCS helps reduce pain. By learning more about these biological markers, the study hopes to improve how SCS is used, making the treatment more personalized and effective for each patient.
People of all genders who are experiencing chronic neuropathic pain and are candidates for spinal cord stimulation may be eligible to join. Participants will have samples of their blood and spinal fluid taken to measure these key substances before and after SCS treatment. This study may also explore how different types of SCS affect pain relief and the role of specific brain cells in the treatment’s success. Overall, the goal is to improve pain management by tailoring therapies to each person’s unique biology.
Gender
ALL
Eligibility criteria
About Pawel Sokal
Pawel Sokal is a clinical trial sponsor with a focus on advancing medical research through well-designed and ethically conducted studies. Committed to innovation and patient safety, Pawel Sokal supports clinical investigations that aim to improve therapeutic outcomes and contribute to the development of new treatment options across various medical fields.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported